2-(4-(3-methoxyphenyl)-5-(pyridin-2-yl)-4H-1,2,4-triazol-3-ylthio)-N-(4-fluorophenyl)acetamide | 943092-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(4-(3-methoxyphenyl)-5-(pyridin-2-yl)-4H-1,2,4-triazol-3-ylthio)-N-(4-fluorophenyl)acetamide
• 英文别名: GJ072；N-(4-fluorophenyl)-2-[[4-(3-methoxyphenyl)-5-pyridin-2-yl-1,2,4-triazol-3-yl]sulfanyl]acetamide
• CAS: 943092-47-5
• 化学式: C₂₂H₁₈FN₅O₂S
• 分子量: 435.482
• InChiKey: CXIQYWLXCWNKRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS<br/>[FR] COMPOSÉS DE TRANSLECTURE DE CODONS DE TERMINAISON PRÉMATURÉS
  申请人：UNIV CALIFORNIA

  公开号：WO2013142346A1

  公开（公告）日：2013-09-26

  Premature termination codons readthrough compounds of formula (lb), composition thereof, and methods of making and using the same are provided.

  提供了式(lb)的早衰终止密码子读通化合物、其组合物以及制备和使用这些化合物的方法。
• Methods for inducing an immune response
  申请人：MOONSHOT PHARMA LLC

  公开号：US11135221B2

  公开（公告）日：2021-10-05

  Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through and inhibition of nonsense-mediated decay (NMD) of messenger RNAs (mRNAs) bearing PTCs.

  本文特别提供了通过促进过早终止密码子（PTC）读通和抑制带有 PTC 的信使核糖核酸（mRNA）的无意义介导衰变（NMD），在个体中产生免疫反应和/或诱导异常（如增殖）细胞表面表达新抗原的组合物和方法。
• PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS
  申请人：The Regents of the University of California

  公开号：EP2828249A1

  公开（公告）日：2015-01-28
• METHODS FOR INDUCING AN IMMUNE RESPONSE BY PROMOTING PREMATURE TERMINATION CODON READ-THROUGH
  申请人：MOONSHOT PHARMA LLC

  公开号：US20190350908A1

  公开（公告）日：2019-11-21

  Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through of messenger RNAs (mRNAs) bearing PTCs.
• METHODS FOR TREATING CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE MODULATORS
  申请人：MOONSHOT PHARMA LLC

  公开号：US20200155519A1

  公开（公告）日：2020-05-21

  Disclosed herein are compositions and methods for treating cancer in a subject. In some embodiments, the methods involve generating an immune response in an individual by inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells. In one embodiment, a method of treating cancer in a subject includes administering amlexanox in combination with immune modulators, such as checkpoint inhibitors, immune co-stimulatory molecules, TLR agonists, and TNFR superfamily agonists. In one embodiment, the checkpoint inhibitors are selected from antibodies against PD-1, PD-L1, and CTLA-4.